Matches in Nanopublications for { ?s ?p "[A phase II trial is ongoing to test the hypothesis that a compound, high-dose medroxyprogesterone acetate (MPA), used as an unconventional gluocorticoid, will stimulate breast cancer cells to reexpress Nm23-H1 and limit subsequent metastatic colonization.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP592203.RAd85dfeq24-iPTgK9wEbHGLRtQe2AUS_8aDG0Su04K28130_assertion description "[A phase II trial is ongoing to test the hypothesis that a compound, high-dose medroxyprogesterone acetate (MPA), used as an unconventional gluocorticoid, will stimulate breast cancer cells to reexpress Nm23-H1 and limit subsequent metastatic colonization.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP592203.RAd85dfeq24-iPTgK9wEbHGLRtQe2AUS_8aDG0Su04K28130_provenance.
- assertion description "[A phase II trial is ongoing to test the hypothesis that a compound, high-dose medroxyprogesterone acetate (MPA), used as an unconventional gluocorticoid, will stimulate breast cancer cells to reexpress Nm23-H1 and limit subsequent metastatic colonization.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[A phase II trial is ongoing to test the hypothesis that a compound, high-dose medroxyprogesterone acetate (MPA), used as an unconventional gluocorticoid, will stimulate breast cancer cells to reexpress Nm23-H1 and limit subsequent metastatic colonization.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP687383.RAC-tGh4R2aoENXWDR6hpdSbtNz5WyVephA9n3zzZkcDY130_assertion description "[A phase II trial is ongoing to test the hypothesis that a compound, high-dose medroxyprogesterone acetate (MPA), used as an unconventional gluocorticoid, will stimulate breast cancer cells to reexpress Nm23-H1 and limit subsequent metastatic colonization.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP687383.RAC-tGh4R2aoENXWDR6hpdSbtNz5WyVephA9n3zzZkcDY130_provenance.
- NP687380.RAXLjRl7-MXcZ2jauftJhpmyMsUljIStXM-rgWWkeUiMQ130_assertion description "[A phase II trial is ongoing to test the hypothesis that a compound, high-dose medroxyprogesterone acetate (MPA), used as an unconventional gluocorticoid, will stimulate breast cancer cells to reexpress Nm23-H1 and limit subsequent metastatic colonization.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP687380.RAXLjRl7-MXcZ2jauftJhpmyMsUljIStXM-rgWWkeUiMQ130_provenance.
- NP592592.RA56LgEYP2o478AoAjzWLVHlS3Wrxgnbtn3clD72CmAmU130_assertion description "[A phase II trial is ongoing to test the hypothesis that a compound, high-dose medroxyprogesterone acetate (MPA), used as an unconventional gluocorticoid, will stimulate breast cancer cells to reexpress Nm23-H1 and limit subsequent metastatic colonization.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP592592.RA56LgEYP2o478AoAjzWLVHlS3Wrxgnbtn3clD72CmAmU130_provenance.